Chronic NaHS treatment is vasoprotective in high-fat-fed ApoE-/- mice

International Journal of Vascular Medicine

Volumn 2013, Issue , 2013, Pages

  Ford, Asha ^a   Al Magableh, Mohammad ^b   Gaspari, Tracey A ^b   Hart, Joanne L ^a  

^a RMIT UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROGEN SULFIDE; PROPARGYLGLYCINE; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE COURSE; LIPID DIET; LONG TERM CARE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; VASCULARIZATION;

EID: 84880170313     PISSN: 20902824     EISSN: 20902832     Source Type: Journal    
DOI: 10.1155/2013/915983     Document Type: Article

References (57)

1. 2S be the third endogenous gaseous transmitter? FASEB Journal 2002 16 13 1792 1798 2-s2.0-0036845556 10.1096/fj.02-0211hyp
2. Hart J. L., Role of sulfur-containing gaseous substances in the cardiovascular system. Frontiers in Bioscience 2011 3 736 749 2-s2.0-79954621298
3. Streeter E., Ng H. H., Hart J. L., Hydrogen sulfide as a vasculoprotective factor. Medical Gas Research 2013 3 1 9
4. Shibuya N., Mikami Y., Kimura Y., Nagahara N., Kimura H., Vascular endothelium expresses 3-mercaptopyruvate sulfurtransferase and produces hydrogen sulfide. Journal of Biochemistry 2009 146 5 623 626 2-s2.0-70449686289 10.1093/jb/mvp111
5. 2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine γ -lyase. Science 2008 322 5901 587 590 2-s2.0-54949084607 10.1126/science.1162667
6. Wang R., Hydrogen sulfide: a new EDRF. Kidney International 2009 76 7 700 704 2-s2.0-70349205750 10.1038/ki.2009.221
7. Yan H., Du J., Tang C., The possible role of hydrogen sulfide on the pathogenesis of spontaneous hypertension in rats. Biochemical and Biophysical Research Communications 2004 313 1 22 27 2-s2.0-0348111406 10.1016/j.bbrc.2003. 11.081
8. Al-Magableh M. R., Hart J. L., Mechanism of vasorelaxation and role of endogenous hydrogen sulfide production in mouse aorta. Naunyn-Schmiedebergs Archives of Pharmacology 2011 383 4 403 413 2-s2.0-79954587083 10.1007/s00210-011-0608-z
9. Fan J., Watanabe T., Inflammatory reactions in the pathogenesis of atherosclerosis. Journal of Ptherosclerosis and Thrombosis 2003 10 2 63 71 2-s2.0-0042510743
10. Weber C., Noels H., Atherosclerosis: current pathogenesis and therapeutic options. Nature Medicine 2011 17 11 1410 1422 2-s2.0-81255188900 10.1038/nm.2538
11. 2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE-/-mice. American Journal of Physiology 2010 298 1 H24 H32 2-s2.0-73549096170 10.1152/ajpheart.00799.2009
12. Lynn E. G., Austin R. C., Hydrogen sulfide in the pathogenesis of atherosclerosis and its therapeutic potential. Expert Review of Clinical Pharmacology 2011 4 1 97 108 2-s2.0-78650489682 10.1586/ecp.10.130
13. Du J., Hui Y., Cheung Y., The possible role of hydrogen sulfide as a smooth muscle cell proliferation inhibitor in rat cultured cells. Heart and Vessels 2004 19 2 75 80 2-s2.0-1642551072 10.1007/s00380-003-0743-7
14. 2S on human aorta smooth muscle cells. FASEB Journal 2006 20 3 553 555 2-s2.0-33645836479 10.1096/fj.05-4712fje
15. Laggner H., Muellner M. K., Schreier S., Hydrogen sulphide: a novel physiological inhibitor of LDL atherogenic modification by HOCl. Free Radical Research 2007 41 7 741 747 2-s2.0-34347259271 10.1080/10715760701263265
16. Muzaffar S., Shukla N., Bond M., Exogenous hydrogen sulfide inhibits superoxide formation, NOX-1 expression and Rac1 activity in human vascular smooth muscle cells. Journal of Vascular Research 2008 45 6 521 528 2-s2.0-54249148441 10.1159/000129686
17. Zhao Z. Z., Wang Z., Li G. H., Hydrogen sulfide inhibits macrophage-derived foam cell formation. Experimental Biology and Medicine 2011 236 2 169 176 2-s2.0-79951640396 10.1258/ebm.2010.010308
18. Wang Y., Zhao X., Jin H., Role of hydrogen sulfide in the development of atherosclerotic lesions in apolipoprotein E knockout mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2009 29 2 173 179 2-s2.0-59449083925 10.1161/ATVBAHA.108.179333
19. Zhang H., Guo C., Wu D., Hydrogen sulfide inhibits the development of atherosclerosis with suppressing CX3CR1 and CX3CL1 expression. PLoS One 2012 7 7, article e41147
20. Zagli G., Patacchini R., Trevisani M., Hydrogen sulfide inhibits human platelet aggregation. European Journal of Pharmacology 2007 559 1 65 68 2-s2.0-33847078111 10.1016/j.ejphar.2006.12.011
21. Sodha N. R., Clements R. T., Feng J., Hydrogen sulfide therapy attenuates the inflammatory response in a porcine model of myocardial ischemia/reperfusion injury. Journal of Thoracic and Cardiovascular Surgery 2009 138 4 977 984 2-s2.0-70349118533 10.1016/j.jtcvs.2008.08.074
22. Zhao X., Zhang L. K., Zhang C. Y., Regulatory effect of hydrogen sulfide on vascular collagen content in spontaneously hypertensive rats. Hypertension Research 2008 31 8 1619 1630 2-s2.0-55449104752
23. + channels contributes to NaHS-induced membrane hyperpolarization and relaxation in the rat coronary artery. Vascular Pharmacology 2010 53 3-4 94 98 2-s2.0-77956183336 10.1016/j.vph.2010.04.004
24. Lee S. W., Cheng Y., Moore P. K., Bian J. S., Hydrogen sulphide regulates intracellular pH in vascular smooth muscle cells. Biochemical and Biophysical Research Communications 2012 418 4 1142 1147 2-s2.0-84857443698 10.1016/j.bbrc.2012.01.113
25. Kiss L., Deitch E. A., Szabo C., Hydrogen sulfide decreases adenosine triphosphate levels in aortic rings and leads to vasorelaxation via metabolic inhibition. Life Sciences 2008 83 17-18 589 594 2-s2.0-53249087745 10.1016/j.lfs.2008.08.006
26. Streeter E., Hart J., Badoer E., An investigation of the mechanisms of hydrogen sulfide-induced vasorelaxation in rat middle cerebral arteries. Naunyn-Schmiedeberg's Archives of Pharmacology 2012 385 10 991 1002 10.1007/s00210-012-0779-2
27. 2S-induced vasorelaxation and underlying cellular and molecular mechanisms. American Journal of Physiology 2002 283 2 H474 H480 2-s2.0-0036073185
28. Cheng Y., Ndisang J. F., Tang G., Cao K., Wang R., Hydrogen sulfide-induced relaxation of resistance mesenteric artery beds of rats. American Journal of Physiology 2004 287 5 H2316 H2323 2-s2.0-7244240892 10.1152/ajpheart.00331.2004
29. Leo C. H., Joshi A., Hart J. L., Woodman O. L., Endothelium-dependent nitroxylmediated relaxation is resistant to superoxide anion scavenging and preserved in diabetic rat aorta. Pharmacological Research 2012 66 5 383 391
30. Leo C. H., Hart J. L., Woodman O. L., 3′4′-dihydroxyflavonol reduces superoxide and improves nitric oxide function in diabetic rat mesenteric arteries. PLoS ONE 2011 6 6, article e20813 2-s2.0-79958092697 10.1371/journal.pone.0020813
31. 2S as a novel endogenous gaseous KATP channel opener. EMBO Journal 2001 20 21 6008 6016 2-s2.0-0035503695 10.1093/emboj/20.21.6008
32. 2+ sparks. American Journal of Physiology 2013 304 11 H1446 H1454 10.1152/ajpheart.00506.2012
33. 2+ sparks to induce cerebral arteriole dilatation. The Journal of Physiology 2012 590 11 2709 2720 10.1113/jphysiol.2011.225128
34. Bucci M., Papapetropoulos A., Vellecco V., Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 10 1998 2004 2-s2.0-77957718685 10.1161/ATVBAHA.110.209783
35. Bucci M., Papapetropoulos A., Vellecco V., cGMPDependent protein kinase contributes to hydrogen sulfide-stimulated vasorelaxation. PLoS One 2012 7 12, article e53319
36. Waldron G. J., Ding H., Lovren F., Kubes P., Triggle C. R., Acetylcholine-induced relaxation of peripheral arteries isolated from mice lacking endothelial nitric oxide synthase. British Journal of Pharmacology 1999 128 3 653 658 2-s2.0-0032701197 10.1038/sj.bjp.0702858
37. Carballal S., Trujillo M., Cuevasanta E., Reactivity of hydrogen sulfide with peroxynitrite and other oxidants of biological interest. Free Radical Biology and Medicine 2011 50 1 196 205 2-s2.0-78650699428 10.1016/j. freeradbiomed.2010.10.705
38. 2S/HS- donor. Free Radical Research 2009 43 6 581 593 2-s2.0-67650889069 10.1080/10715760902977416
39. Whiteman M., Armstrong J. S., Chu S. H., The novel neuromodulator hydrogen sulfide: an endogenous peroxynitrite 'scavenger'? Journal of Neurochemistry 2004 90 3 765 768 2-s2.0-3343017187 10.1111/j.1471-4159.2004. 02617.x
40. Yan S. K., Chang T., Wang H., Wu L., Wang R., Meng Q. H., Effects of hydrogen sulfide on homocysteine-induced oxidative stress in vascular smooth muscle cells. Biochemical and Biophysical Research Communications 2006 351 2 485 491 2-s2.0-33751064582 10.1016/j.bbrc.2006.10.058
41. 2-induced neural injury via enhancing glutamate uptake. Free Radical Biology and Medicine 2008 45 12 1705 1713 2-s2.0-56349137081 10.1016/j.freeradbiomed.2008.09.014
42. Whiteman M., Cheung N. S., Zhu Y. Z., Hydrogen sulphide: a novel inhibitor of hypochlorous acid-mediated oxidative damage in the brain? Biochemical and Biophysical Research Communications 2005 326 4 794 798 2-s2.0-10644266135 10.1016/j.bbrc.2004.11.110
43. Kobayashi S., Inoue N., Azumi H., Expressional changes of the vascular antioxidant system in atherosclerotic coronary arteries. Journal of Atherosclerosis and Thrombosis 2002 9 4 184 190 2-s2.0-0036357328
44. Land W. G., Emerging role of innate immunity in organ transplantation-part I: evolution of innate immunity and oxidative allograft injury. Transplantation Reviews 2012 26 2 60 72 2-s2.0-84859006571 10.1016/j.trre.2011.05.001
45. Brandes R. P., Weissmann N., Schröder K., NADPH oxidases in cardiovascular disease. Free Radical Biology and Medicine 2010 49 5 687 706 2-s2.0-77955096004 10.1016/j.freeradbiomed.2010.04.030
46. 2S-donating sildenafil (ACS6) inhibits superoxide formation and gp91phox expression in arterial endothelial cells: role of protein kinases A and G. British Journal of Pharmacology 2008 155 7 984 994 2-s2.0-56749104311 10.1038/bjp.2008.326
47. Fukao K., Shimada K., Naito H., Voluntary exercise ameliorates the progression of atherosclerotic lesion formation via anti-inflammatory effects in apolipoprotein E-deficient mice. Journal of Atherosclerosis and Thrombosis 2010 17 12 1226 1236 2-s2.0-78650825893
48. Vinh A., Widdop R. E., Chai S. Y., Gaspari T. A., Angiotensin IV-evoked vasoprotection is conserved in advanced atheroma. Atherosclerosis 2008 200 1 37 44 2-s2.0-49749139399 10.1016/j.atherosclerosis.2007.12.042
49. Tesanovic S., Vinh A., Gaspari T. A., Casley D., Widdop R. E., Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arteriosclerosis, Thrombosis, and Vascular Biology 2010 30 8 1606 1613 2-s2.0-77955175630 10.1161/ATVBAHA.110.204453
50. Vinh A., Widdop R. E., Drummond G. R., Gaspari T. A., Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice. Cardiovascular Research 2008 77 1 178 187 2-s2.0-38849168247 10.1093/cvr/cvm021
51. Szabõ C., Hydrogen sulphide and its therapeutic potential. Nature Reviews Drug Discovery 2007 6 11 917 935 2-s2.0-35748959038 10.1038/nrd2425
52. Konno R., Ikeda M., Yamaguchi K., Ueda Y., Niwa A., Nephrotoxicity of D-propargylglycine in mice. Archives of Toxicology 2000 74 8 473 479 2-s2.0-0033626482 10.1007/s002040000156
53. Deleon E. R., Stoy G. F., Olson K. R., Passive loss of hydrogen sulfide in biological experiments. Analytical Biochemistry 2012 421 1 203 207 2-s2.0-84855893273 10.1016/j.ab.2011.10.016
54. Li L., Whiteman M., Guan Y. Y., Characterization of a novel, water-soluble hydrogen sulfide-releasing molecule (GYY4137): new insights into the biology of hydrogen sulfide. Circulation 2008 117 18 2351 2360 2-s2.0-43249105340 10.1161/CIRCULATIONAHA.107.753467
55. Olson K. R., A practical look at the chemistry and biology of hydrogen sulfide. Antioxid Redox Signal 2012 17 1 32 44
56. 2S signalling through protein sulfhydration and beyond. Nature Reviews Molecular Cell Biology 2012 13 8 499 507
57. Calvert J. W., Coetzee W. A., Lefer D. J., Novel insights into hydrogen sulfide-mediated cytoprotection. Antioxidants and Redox Signaling 2010 12 10 1203 1217 2-s2.0-77950852339 10.1089/ars.2009.2882